Publications by authors named "Mike Walton"

Claim this Profile
C
Correction: AT13148 Is a Novel, Oral Multi-AGC Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity.
Timothy A Yap, Mike I Walton, Kyla M Grimshaw, Robert H Te Poele, Paul D Eve

Clin Cancer Res· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A prospective radiostereometric analysis of the stability of a metal-backed glenoid component/autograft composite in reverse shoulder arthroplasty.
Lindsay J Cunningham, Mike Walton, Steve Bale, Ian A Trail

Bone Joint J· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survivorship of Allologous Structural Bone Graft at a Minimum of 2 Years When Used to Address Significant Glenoid Bone Loss in Revision Shoulder Arthroplasty: A Computed Tomographic and Clinical Review.
Aparna Viswanath, Amy K Newell, Lindsay J Cunningham, Mike Walton, Puneet Monga

J Shoulder Elb Arthroplast· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Community Engagement and Data Disclosure in Environmental Health Research.
Erin N Haynes, Sarah Elam, Roxanne Burns, Alonzo Spencer, Elissa Yancey, Mike Walton

Environ Health Perspect· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PRP for Arthroscopic Repair of Medium to Large Rotator Cuff Tears: Letter to the Editor.
Paul M Robinson, Mike Walton, Lennard Funk

Am J Sports Med· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma.
Mike I Walton, Paul D Eve, Angela Hayes, Alan T Henley, Melanie R Valenti

Oncotarget· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rehabilitation following rotator cuff repair: a systematic review.
Chris Littlewood, Marcus Bateman, David Clark, James Selfe, Duncan Watkinson, Mike Walton

Shoulder Elbow· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reinterpretation of O'Brien test in posterior labral tears of the shoulder.
J Matthew Owen, Thomas Boulter, Mike Walton, Lennard Funk, Tanya Anne Mackenzie

Int J Shoulder Surg· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective blubber fatty acid mobilization in lactating gray seals (Halichoerus grypus).
Aline Arriola, Martin Biuw, Mike Walton, Simon Moss, Patrick Pomeroy

Physiol Biochem Zool· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs.
Mike I Walton, Paul D Eve, Angela Hayes, Melanie R Valenti, Alexis K De Haven Brandon

Clin Cancer Res· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity.
Timothy A Yap, Mike I Walton, Kyla M Grimshaw, Robert H Te Poele, Paul D Eve

Clin Cancer Res· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma.
Simon Pacey, Martin Gore, David Chao, Udai Banerji, James Larkin, Mike Walton

Invest New Drugs· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design, synthesis and biological evaluation of 6-pyridylmethylaminopurines as CDK inhibitors.
Stuart C Wilson, Butrus Atrash, Clare Barlow, Susan Eccles, Peter M Fischer, Mike Walton

Bioorg Med Chem· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors.
Simon Pacey, Richard H Wilson, Mike Walton, Martin M Eatock, Anthea Hardcastle

Clin Cancer Res· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930.
Timothy A Yap, Mike I Walton, Lisa-Jane K Hunter, Melanie Valenti, Alexis de Haven Brandon

Mol Cancer Ther· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AT7867 is a potent and oral inhibitor of AKT and p70 S6 kinase that induces pharmacodynamic changes and inhibits human tumor xenograft growth.
Kyla M Grimshaw, Lisa-Jane K Hunter, Timothy A Yap, Simon P Heaton, Mike I Walton

Mol Cancer Ther· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises.
Timothy A Yap, Michelle D Garrett, Mike I Walton, Florence Raynaud, Johann S de Bono

Curr Opin Pharmacol· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An evaluation of the ability of pifithrin-alpha and -beta to inhibit p53 function in two wild-type p53 human tumor cell lines.
Mike I Walton, Stuart C Wilson, Ian R Hardcastle, Amin R Mirza, Paul Workman

Mol Cancer Ther· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogen-activated protein kinase pathway.
Steven R Whittaker, Mike I Walton, Michelle D Garrett, Paul Workman

Cancer Res· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The contemporary drug development process: advances and challenges in preclinical and clinical development.
Michelle D Garrett, Mike I Walton, Edward McDonald, Ian Judson, Paul Workman

Prog Cell Cycle Res· December 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in human colon cancer models.
Yuen-Li Chung, Helen Troy, Udai Banerji, Laura E Jackson, Mike I Walton

J Natl Cancer Inst· November 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A rationale for the clinical development of the thymidylate synthase inhibitor ZD9331 in ovarian and other solid tumours.
Ann L Jackman, Camille J Melin, Rosemary Kimbell, Lisa Brunton, G Wynne Aherne, Mike Walton

Biochim Biophys Acta· July 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis